Life & Brain

Executive Summary

Life & Brain GmbH is a German biotechnology service provider based on the University Hospital Bonn campus, specializing in omics analysis (genomics, epigenetics, proteomics) and iPSC-based cellular models. Founded in 2006, the company acts as a translational bridge, converting academic research into quality-controlled products and services for drug discovery. Despite its niche in providing premium analytical services, Life & Brain lacks recent funding rounds, disclosed revenues, or clinical-stage pipelines, positioning it as a stable but low-visibility private entity. The company’s value lies in its ability to support pharma and biotech R&D through standardized, high-quality data and cell models, which are increasingly critical for precision medicine. However, without a clear product portfolio or public catalysts, near-term growth is tied to broader industry demand for outsourced omics services.

Upcoming Catalysts (preview)

• Q4 2026New Partnership with Major Pharma for iPSC-Based Drug Screening40% success
• Q2 2027Launch of Multi-Omics Integration Service Platform50% success
• Q1 2028Strategic Expansion into CRISPR-Based Functional Genomics Services30% success